Sacubitril/Valsartan (LCZ696) 是由 Valsartan (an ARB) 和 Sacubitril (AHU377) 组成,摩尔比为 1:1,是一种首创的血管紧张素受体-脑啡肽酶 (ARN) 双抑制剂,用于研究高血压和心力衰竭。它可通过抑制炎症、氧化应激和细胞凋亡来改善糖尿性心肌病 Information Sacubitril/valsartan (LCZ696) Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3. Targets RAAS In vivo In double-transgenic rats overexpressing human renin and angiotensinogen and plasma atrial natriuretic peptide immunoreactivity, LCZ696 (60 mg/kg p.o.) induces a dose-dependent and long-lasting reduction in mean arterial pressure (MAP), and stimulates a rapid and dose-dependent augmentation of plasma ANP immunoreactivity. In rat myocardial infarction (MI) model, LCZ696 (68 mg/kg p.o.) attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
Sacubitril/valsartan (LCZ696)
CAS number:936623-90-4 molecular formula:C24H29N5O3·C24H29NO5·5/2H2O·3Na
overview
Specs
| Chinese alias | - | ||
| English alias | Sacubitril mixture with Valsartan | Valsartan | Sacubitril | LCZ696 | ||
| CAS number | 936623-90-4 | molecular formula | C24H29N5O3·C24H29NO5·5/2H2O·3Na |
| molecular weight | 915.98 g/mol | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
No upstream information yet
No downstream information yet




